← Human Trials & Peer-Reviewed Studies
Ghrelin potentiates growth hormone secretion driven by putative somatostatin withdrawal and resists inhibition by human corticotropin-releasing hormone
Plain-language guide to PMID 16537682 (2006): double-blind randomized controlled trial study of Ghrelin and Somatostatin.
Key Facts
- PMID
- 16537682
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2006
- Study type
- Randomized Controlled Trial
- Authors
- Veldhuis JD et al. (6 authors)
- DOI
- 10.1210/jc.2005-2718
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Ghrelin and Somatostatin, published as a randomized controlled trial.
The objective of this study was to test the hypothesis that ghrelin can stimulate GH secretion in the absence or presence of somatostatin withdrawal (induced by l-arginine infusion) and stress-like drive by CRH.
Why It Was Studied
Ghrelin is a 28-amino acid, Ser(3)-octanoylated peptide that stimulates GH secretion in vivo and in vitro.
Beyond the capability of ghrelin to synergize with GHRH, little is known about multipeptide modulation of ghrelin's actions in humans.
Who Took Part
By PubMed's age tags, the people studied were middle-aged adults and older adults, women only.
Subjects were given an iv infusion of saline and/or l-arginine or human CRH, followed by a bolus iv injection of ghrelin.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Random assignment meant chance, not the researchers, decided who got Ghrelin and who got the comparison, which limits bias.
Blinding on both sides kept the participants and researchers unaware of who received Ghrelin.
The comparison arm used a placebo, so changes seen with Ghrelin could be set against what happens without it.
In the crossover set-up each of the participants took both Ghrelin and the comparison in turn, acting as their own control.
This was a randomized, double-blind, placebo-controlled, cross-over interventional study.
This study was performed at an academic medical center.
What Was Measured
PubMed files the paper under topics including Arginine, Corticotropin-Releasing Hormone, Drug Synergism, Ghrelin, Human Growth Hormone, Peptide Hormones and Somatostatin.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Ghrelin and Somatostatin.
The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2006 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Ghrelin compound page and the Somatostatin compound page, all human trials.
Our Notes on the Compounds
Ghrelin: A 28-amino-acid stomach hormone that signals hunger and triggers growth hormone release; studied in human trials as an infusion.
Somatostatin: A 14-amino-acid hormone that switches off the release of several other hormones, including growth hormone and insulin.
ACTH (Corticotropin): The 39-amino-acid pituitary hormone that drives cortisol production; given as repository corticotropin (Acthar Gel).
Related Pages
- Ghrelin in the library
- Somatostatin in the library
- ACTH (Corticotropin) in the library
- CRH (Corticotropin-Releasing Hormone) in the library
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.